| Name | Title | Contact Details |
|---|
Alucent Biomedical, Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah and is the first company to bring a novel, locally delivered biotechnology treatment to a market traditionally dominated by medical device solutions. Alucent was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS). NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency.
Sierra Oncology is a clinical stage drug development company advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Our lead drug candidate, momelotinib, is a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing a range of meaningful anemia benefits, including eliminating or reducing the need for frequent blood transfusions, as well as achieving substantive spleen and constitutional symptom control. We are also advancing SRA737 and SRA141. SRA737, is a potent, highly selective, orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1). We are pursuing an innovative development plan for SRA737, which is currently being evaluated in two Phase 1/2 clinical trials in patients with advanced cancer. SRA737-01 is intended to evaluate SRA737`s potential to induce synthetic lethality as monotherapy, while SRA737-02 is intended to evaluate the combination of SRA737 potentiated by subtherapeutic, low dose gemcitabine. Concurrently, we are conducting preclinical research evaluating SRA737 in combination with other DDR-targeted agents, including PARP inhibitors, as well as with immuno-oncology therapeutics, that may guide a potential next wave of clinical development for our asset, possibly further broadening its therapeutic utility. SRA141, a potent, selective, orally bioavailable small molecule inhibitor of cell division cycle 7 kinase (Cdc7). Cdc7 is a key regulator of DNA replication and is involved in the DDR network, making it a compelling emerging target for potential treatment across a broad range of tumor types. An Investigational New Drug Application (IND) submission to the U.S. Food and Drug Administration (FDA) is being prepared in order to commence clinical trials with this drug candidate.
Perseus is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D.
Transcriptic is a very small company. We like it that way. Our work culture is an unstructured environment where you can do your best work supported by a group of your peers. Everyone sets their own goals, and everyone is empowered to think creatively. We work hard and we focus, but we don`t do all-nighters or heroic pushes. Grinding yourself into the ground is a fast way to introduce bugs. Life science demands precision; we take our time and we get it right. We use commercial-off-the-shelf solutions when they`re available, and we aren`t afraid to open them up to get to more exacting standards—and if we can`t find it, we build it. We`re completely devoted to solving Transcriptic`s challenges as cleverly as possible to build solid, reliable, intelligent solutions.